G. Sesti Et Al. , "DUALVIII: more patients met treatment targets with IDegLira (insulin degludec/liraglutide) vs IGlar U100 by week 26 in a 104 week randomised trial mirroring clinical practice," 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) , vol.62, Barcelona, Spain, 2019
Sesti, G. Et Al. 2019. DUALVIII: more patients met treatment targets with IDegLira (insulin degludec/liraglutide) vs IGlar U100 by week 26 in a 104 week randomised trial mirroring clinical practice. 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) , (Barcelona, Spain).
Sesti, G., Bardtrum, L., Daddelen, S., Halladin, N., Haluzik, M., Orsy, P., ... Rodriguez, M.(2019). DUALVIII: more patients met treatment targets with IDegLira (insulin degludec/liraglutide) vs IGlar U100 by week 26 in a 104 week randomised trial mirroring clinical practice . 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Barcelona, Spain
Sesti, G. Et Al. "DUALVIII: more patients met treatment targets with IDegLira (insulin degludec/liraglutide) vs IGlar U100 by week 26 in a 104 week randomised trial mirroring clinical practice," 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Barcelona, Spain, 2019
Sesti, G. Et Al. "DUALVIII: more patients met treatment targets with IDegLira (insulin degludec/liraglutide) vs IGlar U100 by week 26 in a 104 week randomised trial mirroring clinical practice." 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) , Barcelona, Spain, 2019
Sesti, G. Et Al. (2019) . "DUALVIII: more patients met treatment targets with IDegLira (insulin degludec/liraglutide) vs IGlar U100 by week 26 in a 104 week randomised trial mirroring clinical practice." 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) , Barcelona, Spain.
@conferencepaper{conferencepaper, author={G. Sesti Et Al. }, title={DUALVIII: more patients met treatment targets with IDegLira (insulin degludec/liraglutide) vs IGlar U100 by week 26 in a 104 week randomised trial mirroring clinical practice}, congress name={55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD)}, city={Barcelona}, country={Spain}, year={2019}}